预计扭亏！这家公司终止重大资产重组！

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. has officially terminated its major asset restructuring plan after nearly six months of planning due to a lack of consensus among the parties involved in the transaction [1] Group 1: Company Background and Performance Challenges - The company, originally listed as Hong Kong and Macau Industry in 1992, has undergone multiple ownership changes and name changes, finally being renamed Nanhua Biopharmaceutical in 2015 to enter the biomedicine sector [2] - The company has two main businesses: biomedicine (stem cell and immune cell storage) and energy conservation and environmental protection, but its performance has been inconsistent, with revenue still heavily reliant on cell storage [2] - The company has oscillated between being under special treatment (ST) and being delisted, facing continuous losses from 2014 to 2015, leading to its first ST designation in 2016, and again facing ST status in 2019 due to two consecutive years of losses [2] Group 2: Termination of Restructuring and Financial Impact - The company announced the termination of its plan to acquire a 51% stake in Hunan Huize Biopharmaceutical Technology Co., Ltd. due to the inability to reach an agreement on the transaction terms, with the termination not expected to have a significant adverse impact on its operations or financial status [3][4] - The company committed to not planning any major asset restructuring for at least one month following the announcement [4] Group 3: Financial Forecast and Recovery - Alongside the termination announcement, the company projected its 2025 revenue to be between 385 million to 425 million yuan, a significant increase from approximately 130 million yuan in the previous year [5] - The company expects to achieve a net profit attributable to shareholders of between 28.5 million to 32.5 million yuan in 2025, marking a turnaround from a loss of 19.846 million yuan in the same period last year [6] - The recovery is primarily driven by the acquisition of Loudi Jinhong New Materials Co., Ltd., which has enhanced revenue from resource recycling businesses, rather than the terminated biopharmaceutical acquisition [6][7]